News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
834,848 Results
Type
Article (85851)
Company Profile (649)
Press Release (748348)
Section
Business (232101)
Career Advice (4123)
Deals (39695)
Drug Delivery (124)
Drug Development (90724)
Employer Resources (195)
FDA (17961)
Job Trends (17298)
News (395317)
Policy (39625)
Tag
Academia (2978)
Alliances (56577)
Alzheimer's disease (1407)
Antibody-drug conjugate (ADC) (117)
Approvals (17942)
Artificial intelligence (189)
Bankruptcy (399)
Best Places to Work (12512)
Biotechnology (447)
Breast cancer (193)
Cancer (1599)
Career advice (3524)
CAR-T (137)
Cell therapy (393)
Clinical research (72260)
Collaboration (648)
Compensation (321)
COVID-19 (2812)
C-suite (162)
Data (1441)
Diabetes (155)
Diagnostics (6709)
Earnings (94655)
Employer resources (166)
Events (127484)
Executive appointments (501)
FDA (18701)
Funding (538)
Gene therapy (272)
GLP-1 (694)
Government (5059)
Healthcare (20725)
Infectious disease (2908)
Inflammatory bowel disease (138)
Interviews (811)
IPO (17661)
Job creations (5182)
Job search strategy (2860)
Layoffs (514)
Legal (10041)
Lung cancer (237)
Manufacturing (231)
Medical device (14276)
Medtech (14281)
Mergers & acquisitions (22180)
Metabolic disorders (506)
Neuroscience (1808)
NextGen: Class of 2025 (7661)
Non-profit (5054)
Northern California (1926)
Obesity (274)
Opinion (262)
Patents (152)
People (64557)
Pharmaceutical (131)
Phase I (22313)
Phase II (31416)
Phase III (23621)
Pipeline (708)
Postmarket research (3542)
Preclinical (10007)
Radiopharmaceuticals (246)
Rare diseases (316)
Real estate (7375)
Regulatory (26195)
Research institute (2641)
Resumes & cover letters (649)
Southern California (1637)
Startups (4281)
United States (16862)
Vaccines (677)
Weight loss (211)
Date
Today (59)
Last 7 days (677)
Last 30 days (2261)
Last 365 days (31817)
2025 (4455)
2024 (34071)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1263)
Arizona (226)
Asia (49586)
Australia (8754)
California (4384)
Canada (1396)
China (388)
Colorado (143)
Connecticut (184)
Europe (113463)
Florida (538)
Georgia (118)
Illinois (408)
Indiana (239)
Maryland (731)
Massachusetts (3523)
Michigan (171)
Minnesota (285)
New Jersey (1257)
New York (1236)
North Carolina (913)
Northern California (1926)
Ohio (142)
Pennsylvania (942)
South America (1646)
Southern California (1637)
Texas (573)
Washington State (451)
834,848 Results for "peak bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bankruptcy
Biopharma Bankruptcies Still At Peak, With Little Relief in Sight
2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024.
February 19, 2025
·
5 min read
·
Annalee Armstrong
Deals
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
Akari Therapeutics, Plc and Peak Bio Inc. announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC platform technology and Akari’s PAS-nomacopan Geographic Atrophy program.
May 1, 2024
·
16 min read
Press Releases
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
November 15, 2024
·
8 min read
Press Releases
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
November 8, 2024
·
12 min read
Deals
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Akari Therapeutics, Plc and Peak Bio Inc. announce a definitive agreement to merge as equals in an all-stock transaction.
March 5, 2024
·
17 min read
Biotech Bay
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Akari Therapeutics, Plc and Peak Bio Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction.
March 5, 2024
·
17 min read
Press Releases
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
October 15, 2024
·
13 min read
Biotech Bay
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
Peak Bio, Inc. (“Peak Bio” or the “Company”) (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin Analogs” by The United States Patent and Trademark Office (USPTO).
January 4, 2024
·
7 min read
Immuron CEO Steven Lydeamore to present at Peak Sky High
Immuron Limited, an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management’s Peak Sky High luncheon in Melbourne on June 1, 2024.
May 31, 2024
·
6 min read
Business
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
Peak Bio, Inc., is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases.
August 31, 2023
·
6 min read
1 of 83,485
Next
